# PICKRCC (NCT03905889)

> A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma

No report yet. It can be ordered.

- Drugs tested: abemaciclib plus sunitinib
- Indication: metastatic renal cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03905889
- Phase: PHASE1
- Status: TERMINATED
- Sponsor: Brown University
- Conditions: Renal Cell Carcinoma Metastatic
- Interventions: Abemaciclib; Sunitinib
- Enrollment: 3
- Primary outcome: Maximum tolerated dose (MTD)
- Primary outcome: Continued Toxicity assessment of the maximum tolerated dose (i.e the recommended Phase II dose) of Abemaciclib and Sunitinib as determined from the from dose escalation phase.
- Primary outcome: Pharmacokinetic Assessment of Abemaciclib and Sunitinib trough levels at steady state

## Indexed commentary on PICKRCC so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=pickrcc-nct03905889